Switch theme
Sign up to access all valuation multiples
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
2011
147
LTM Revenue $10.0M
LTM EBITDA -$160M
-$83.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Caribou Biosciences has a last 12-month revenue (LTM) of $10.0M and a last 12-month EBITDA of -$160M.
In the most recent fiscal year, Caribou Biosciences achieved revenue of $10.0M and an EBITDA of -$163M.
Caribou Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Caribou Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.0M | XXX | $10.0M | XXX | XXX | XXX |
| Gross Profit | $10.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$160M | XXX | -$163M | XXX | XXX | XXX |
| EBITDA Margin | -1601% | XXX | -1628% | XXX | XXX | XXX |
| EBIT | -$166M | XXX | -$167M | XXX | XXX | XXX |
| EBIT Margin | -1671% | XXX | -1667% | XXX | XXX | XXX |
| Net Profit | -$150M | XXX | -$149M | XXX | XXX | XXX |
| Net Margin | -1510% | XXX | -1492% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Caribou Biosciences's stock price is $1.
Caribou Biosciences has current market cap of $98.6M, and EV of -$83.7M.
See Caribou Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$83.7M | $98.6M | XXX | XXX | XXX | XXX | $-1.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Caribou Biosciences has market cap of $98.6M and EV of -$83.7M.
Caribou Biosciences's trades at -8.4x EV/Revenue multiple, and 0.5x EV/EBITDA.
Equity research analysts estimate Caribou Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Caribou Biosciences has a P/E ratio of -0.7x.
See valuation multiples for Caribou Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $98.6M | XXX | $98.6M | XXX | XXX | XXX |
| EV (current) | -$83.7M | XXX | -$83.7M | XXX | XXX | XXX |
| EV/Revenue | -8.4x | XXX | -8.4x | XXX | XXX | XXX |
| EV/EBITDA | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | -8.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCaribou Biosciences's last 12 month revenue growth is 57%
Caribou Biosciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.2M for the same period.
Caribou Biosciences's rule of 40 is -269% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Caribou Biosciences's rule of X is -1458% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Caribou Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 57% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1601% | XXX | -1628% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | -269% | XXX | -1571% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1458% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1302% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1767% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Caribou Biosciences acquired XXX companies to date.
Last acquisition by Caribou Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Caribou Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Caribou Biosciences founded? | Caribou Biosciences was founded in 2011. |
| Where is Caribou Biosciences headquartered? | Caribou Biosciences is headquartered in United States of America. |
| How many employees does Caribou Biosciences have? | As of today, Caribou Biosciences has 147 employees. |
| Who is the CEO of Caribou Biosciences? | Caribou Biosciences's CEO is Dr. Rachel Haurwitz, PhD. |
| Is Caribou Biosciences publicy listed? | Yes, Caribou Biosciences is a public company listed on NAS. |
| What is the stock symbol of Caribou Biosciences? | Caribou Biosciences trades under CRBU ticker. |
| When did Caribou Biosciences go public? | Caribou Biosciences went public in 2021. |
| Who are competitors of Caribou Biosciences? | Similar companies to Caribou Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Caribou Biosciences? | Caribou Biosciences's current market cap is $98.6M |
| What is the current revenue of Caribou Biosciences? | Caribou Biosciences's last 12 months revenue is $10.0M. |
| What is the current revenue growth of Caribou Biosciences? | Caribou Biosciences revenue growth (NTM/LTM) is 57%. |
| What is the current EV/Revenue multiple of Caribou Biosciences? | Current revenue multiple of Caribou Biosciences is -8.4x. |
| Is Caribou Biosciences profitable? | Yes, Caribou Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Caribou Biosciences? | Caribou Biosciences's last 12 months EBITDA is -$160M. |
| What is Caribou Biosciences's EBITDA margin? | Caribou Biosciences's last 12 months EBITDA margin is -1601%. |
| What is the current EV/EBITDA multiple of Caribou Biosciences? | Current EBITDA multiple of Caribou Biosciences is 0.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
